Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Becton Dickinson holds a cautious analyst view, shares trade below recent targets - Ad-hoc-news.de

AI-generated analysis

πŸ“‰ Bank of America lowered its Becton Dickinson price target from $177 to $170 while reiterating a Neutral rating.

⚠️ Analysts cited a softer utilization environment and inflation risks for 2027 as key concerns for the medtech sector.

πŸ“Š MarketBeat consensus data shows an average target price of $140.37 with a split of seven Buy, eight Hold, and one Sell ratings.

πŸ’° Becton Dickinson shares closed at $145.43 on June 23, 2026, representing a market cap of $42.5 billion.

πŸ“‰ The stock is currently trading approximately 49% below its all-time high of $287.32 reached in July 2023.

πŸ₯ The company generates revenue from medical-surgical products including syringes, needles, and the BD Venflon peripheral IV catheter line.

πŸ“ˆ BDX is listed on the NYSE and is a component of the S&P 500 healthcare sector alongside peers like Medtronic.

πŸ”„ Recent intraday trading saw a 2.78% move to $144.62 at 15:04 Eastern time on June 22, 2026.

Bullish Signals
  • BDX maintains a presence in the S&P 500 healthcare cohort with established revenue streams from global vascular access procedures.
  • The company possesses a well-known product portfolio including syringes, needles, and infusion therapy systems used worldwide.
Risk Factors
  • Bank of America explicitly cited a softer utilization environment as a reason for lowering its price target.
  • Analysts are concerned about inflation risks impacting the wider medtech sector in 2027.
  • The stock trades materially below large-cap medtech averages, indicating valuation pressure relative to peers.
  • Current trading levels are approximately 49% below the all-time high, reflecting a significant de-rating in the sector.
Full Analysis
Becton Dickinson (BDX) faces a cautious outlook as Bank of America recently lowered its price target from $177 to $170 and maintained a Neutral rating. The analyst cited a softer utilization environment and inflation risks for the wider medtech sector in 2027 as primary drivers for the adjustment. Market consensus remains mixed, with MarketBeat data showing an average target price of $140.37 based on 16 Wall Street analysts. The current split includes seven Buy, eight Hold, and one Sell recommendation, resulting in an overall 'Hold' consensus rating that reflects divergent views on growth versus margin pressure. Shares of the NYSE-listed medical device group are trading at $145.43 as of June 23, 2026, which is approximately 49% below its all-time high of $287.32 reached in July 2023. The company generates significant revenue from medical-surgical products like syringes and the BD Venflon peripheral IV catheter line used globally for vascular access procedures. Despite being part of the S&P 500 healthcare cohort alongside peers like Medtronic, BDX trades materially below large-cap medtech averages on valuation metrics. The stock recently experienced a 2.78% intraday move to $144.62, highlighting ongoing volatility and investor scrutiny regarding sector-wide headwinds.